9 May 2019 07:00
Yourgene Health plc
("Yourgene," the "Company")
Directors' dealing and warrant extension
Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday by Barry Hextall and Hayden Jeffreys, both directors of the Company, that they respectively purchased 89,551 and 222,348 ordinary shares of 0.10p each in the Company yesterday at an average price of 11.2 pence per ordinary share. The table below details each directors' shareholdings:
Director | Shareholding prior to purchase of shares | Number of ordinary shares purchased | Shareholding following purchase of shares | Ordinary shares held as percentage of issued voting share capital |
Barry Hextall | 432,518 | 89,551 | 522,069 | 0.09% |
Hayden Jeffreys | 0 | 222,348 | 222,348 | 0.04% |
Extension of warrant
Furthermore, the Company announces that it has agreed to extend the exercise period by a year of a warrant granted over 1,411,227 ordinary shares that was scheduled to expire on 13 June 2019.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact: | |
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@yourgene-health.com
| Tel: +44 (0)16 1667 1053
|
Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie
| Tel: +44 (0)20 7213 0880 |
Stifel Nicolaus Europe Limited (Broker) Nicholas Moore / Matthew Balwat / Ben Maddison
| Tel: +44 (0)20 7710 7600 |
Vigo Communications Ben Simons / Fiona Henson / Antonia Pollock yourgene@vigocomms.com
| Tel: +44 (0)20 7390 0234
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.
Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | (i) Barry Hextall (ii) Hayden Jeffreys | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | (i) Chief Financial Officer (ii) Chief Operating Officer | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Yourgene Health plc | |||||
b. | LEI | 213800UUIT8BZE7QEH33 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 0.10p each
ISIN: GB00BN31ZD89 | |||||
b. | Nature of the transaction | Purchase of ordinary shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
(i) 11.5p (ii) 11.5p | (i) 89,551 (ii) 222,348 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
311,899
11.5p
| |||||
e. | Date of the transaction | 8 May 2019 | |||||
f. | Place of the transaction | London Stock Exchange | |||||